Table 1

Analysis and outcome of patients with positive sentinel lymph node

PatientSLNFIGO stageHistologyGLSVIAge (years)SLN+Adjuvant treatmentRecurrence
11IB1SquamousG256ITCNo
22IB1*SquamousG277ITCXNo
33IA1SquamousG2+47ITCXNo
44IA2SquamousG1+27MACXNo
55IB1Adenocarcinoma38ITCNo
66IB1SquamousG149ITC
77IB1SSquamousG249ITCXYes
8MAC
89IB1Squamous35MICNo
910IB1AdenocarcinomaG332MACXNo
1011IB1Adenocarcinoma+29MICNo
1112IB1SquamousG354MACXNo
13MAC
1214IB1**SquamousG1_46MICXNo
1315IB1*SquamousG2NA43MACXNo
1416IB1SquamousG148MICNo
17MIC+ITCNo
1518IB1*SquamousG3+45MACXNo
19MAC
1620IB1AdenocarcinomaG2+31MACXNo
1721IB1AdenocarcinomaG244MACXNo
1822IB1Squamous64MICYes
1923IB1AdenocarcinomaNA46ITCNo
2024IB1SquamousG335ITCNo
25MIC
2126IB1Squamous51MIC+ITCNo
  • *In patients 2, 13, and 15 a parametrial involvement was demonstrated at the definitive pathology.

  • †In patient 12 the final tumor size after pathologic analysis was >4 cm.

  • FIGO, International Federation of Gynecology and Obstetrics; G, grade;ITC, isolated tumor cells;LVSI, lymph-vascular space involvement;MAC, macrometastasis;MIC, micrometastasis;NA, not available; SLN, sentinel lymph node.